February 6th 2025
Study author Erin McClure, MD, discusses how IGSRT offers consistent NMSC recurrence rates across socioeconomic and comorbidity factors, reinforcing its role as a first-line treatment.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Targeted therapy for skin malignancies
January 22nd 2019The past decade has seen significant advances in the understanding of molecular pathogenesis of skin cancer leading to the development of targeted treatments and immunotherapies that have dramatically improved progression free survival and even overall survival in melanoma, basal cell carcinoma (BCC) and even some rarer cutaneous carcinomas.
AAD updates cutaneous melanoma guidelines
January 7th 2019Treatment options for metastatic melanoma have greatly improved, including in the adjuvant setting, and these advances are reflected in the recently updated American Academy of Dermatology clinical guidelines on the management of primary cutaneous melanoma. Find out what has changed in this article.
Off-label uses for fluorouracil cream not always based on strong evidence
November 13th 2018Topical 5‐fluorouracil is FDA-approved to treat actinic keratoses and superficial basal cell carcinoma, but it is commonly used off-label to treat a number of other skin conditions, such as squamous cell carcinoma despite strong evidence.
Topical 5-fluorouracil still may be the best bet in actinic keratoses
October 18th 2018Topical 5-fluorouracil (5-FU), which is FDA approved for treating actinic keratoses and superficial basal cell carcinoma, shows the strongest evidence of effectiveness for these two conditions plus squamous cell carcinoma, according to a comprehensive systematic review.
A review of treatment for dermatofibrosarcoma
September 17th 2018Dermatofibrosarcoma is a common, but unusual locally aggressive cutaneous tumor. Its characteristic tentacle can grow into surrounding fat, muscle and even bone. For dermatologists this means that understanding treatment options is a priority, says a physician reporting from EADV 2018.
Surgical treatment for basal cell carcinomas still the best bet
September 17th 2018There are many non-surgical treatments for basal cell carcinomas, but a physician reporting at EADV last week said new treatments should be compared against surgery, which has the highest cure rate and lowest rate of recurrence.
Treating moles and melanoma during pregnancy
September 17th 2018A pregnancy-associated melanoma (PAM) prognosis does not appear to be worse than melanoma in non-pregnant controls, researchers reported at EADV. Nonetheless, measures should be taken to protect the fetus in the treatment and imaging of PAM.
Advent of immunotherapy may require a new, expanded role for dermatologists
September 14th 2018With immunotherapy as a key treatment for melanoma, dermatologists should be prepared to treat its cutaneous side effects and refer for adrenal sufficiency, uveitis, thyroid disease and other non-cutaneous side effects.
EADV report highlights the future of checkpoint inhibitors in advanced melanoma
September 14th 2018Checkpoint inhibitors have clearly changed the prognosis of melanoma, yet the search for evidence-based answers to these and other questions regarding their use continues, experts report at EADV this week.